AO-COMPLEX (= antioxidants complex) consists of a combination of as many as 8 very powerful antioxidants. Therefore AO-Complex gives the body protection against the damaging effects of oxidative stress.
The degree of exposure of our body to oxidative stress is an important health parameter. Numerous studies indicate that the more oxidative stress your body experiences on a daily basis, the higher the incidence of degenerative diseases.
Whoever lives in a highly-developed country, economically, is continually exposed to high levels of oxidative stress. Pollution, western eating habits, stress, and radiation are responsible for an increase in the production of free radicals. Our body is not capable of neutralising these enormous
amounts of free radicals that may cause degenerative diseases.
Nowadays, the intake of a protective antioxidants complex (AO-complex) is indispensable in the west to maintain optimum health. This is particularly important for smokers, athletes, persons with an irregular day-night rhythm, and consumers of alcohol,...
Instruction of use
1 to 2 capsules per day with the meal.
Should not be used for children under the age of 12.
Do not exceed the recommended daily dose.
Keep out of reach of young children.
Nutritional supplements should not replace a varied and balanced diet and a healthy lifestyle.
Children, pregnant women and women who are breastfeeding, consult your pharmacist before use.
Check with simultaneous intake of medicines.
The intake should be limited to a few weeks / months.
Range of usage
• Anti-aging (organs and skin)
CompositionIngredients per 2 vegetable capsules
Alpha lipoic acid 590mg, Anti-caking agents (Magnesium silicate, Magnesium stearate, Silicon dioxide), Vegetable capsule (Hypromellose), L-carnosine 200mg, Solanum lycopersicum L. (Tomato) extract 120mg (contains 6mg Lycopene), N-acetyl-L-cysteine 100mg, Tagetes erecta L. (Large African Anise) extract 30mg (contains 6mg of Lutein), Vitamin E (DL-alpha-tocopheryl acetate) 20mg (166.67% RI), Zinc (Zinc Picolinate) 20mg (200% RI), Selenium (L-selenomethionine) 100mcg (181.82% RI)
RI: Reference intakes
ReferencesShay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790:1149–1160.
Wang Y, Li X, Guo Y, Chan L, Guan X. Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism. 2010;59:967–976
Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation. 2008;117:421–428
Patel MS, Packer L, editors. Lipoid acid. energy production, antioxidant activity, and health effects. Boca Raton: CRC Press, Taylor & Francis Group; 2008.
Koh EH, Cho EH, Kim MS, Park JY, Lee KU. Effects of alpha-lipoic acid on AMP-activated protein kinase in different tissues: therapeutic implications for the metabolic syndrome. In: Patel MS, Packer L, editors. Lipoic Acid: Energy Production, Antioxidant Activity, and Health Effects. Boca Raton, Florida: CRC Press/Taylor & Francis Group; 2008. pp. 495–519
Maczurek AE, Krautwald M, Steele ML, et al. Lipoic acid as a novel treatment for mild cognitive impairment and early-stage Alzheimer’s disease. In: Packer L, Sies H, Eggersdorfer M, Cadenas E, editors. Micronutrients and Brain Health. Boca Raton, Florida: CRC Press/Taylor & Francis Group; 2009. pp. 133–147.
Cho KJ, Moon HE, Moini H, Packer L, Yoon DY, Chung AS. Alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways. J Biol Chem. 2003;278:34823–34833
WJ, Wei H, Hagen T, Frei B. Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc Natl Acad Sci USA. 2007;104:4077–4082
Babizhayev MA, Deyev AI, Yermakova VN, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D 2002;3(2):87-103
Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, Komen J. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neu-rol 2002 Nov;17(11):833-7.
Chez, Michael G., Buchanan, Cathleen P., and Jamie Komen. L-Carnosine Therapy for Intractable Epilepsy in Childhood: Effect on EEG. Epilepsia 2002; 43(7): 65.
Dukic-Stefanovic S, Schinzel R, Riederer P, Munch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology. 2001;2(1):19-34.
Gariballa SE, Sinclair AJ. Carnosine: physiological properties and therapeutic potential. Age Ageing. 2000 May;29(3):207-10.
Hipkiss AR, Brownson C, Bertani MF, Ruiz E, Ferro A. Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci. 2002 Apr;959:285-94.
Hipkiss AR, Brownson C. A possible new role for the anti-ageing peptide carnosine. Cell Mol Life Sci. 2000 May;57(5):747-53.
Hipkiss AR. Carnosine. a protective, anti-ageing peptide? Int J Biochem Cell Biol. 1998, 30: S63-868.
Hipkiss AR, Brownson C. Carnosine reacts with protein carbonyl groups: another possible role for the anti-ageing peptide? Biogerontology. 2000;1(3):217-23.
Horning MS, Blakemore LJ, Trombley PQ. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res. 2000 Jan 3;852(1):56-61.
Marchis, S. De.; Modena, C.; Peretto, P.; Migheli, A.; Margolis, F.L.; & A. Fasolo. Carnosine-Related Di-peptides in Neurons and Gilia. Biochemistry (Moscow). Vol. 65 (7) 2000, 824-833.
Preston J et al. Toxic effects of B-amyloid on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and B-alanine. Neuroscience letters 1998, 242; 105-108.
Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med. 1992;13(5):379-444.
Stuerenburg HJ. The roles of carnosine in aging of skeletal muscle and in neuromuscular diseases. Bio-chemistry (Mosc). 2000 Jul;65(7):862-5.
Stvolinsky SL, Dobrota D. Anti-ischemic activity of carnosine. Biochemistry (Mosc). 2000 Jul;65(7):849-55.
Trombley, P.Q.; Horning, M.S.; & L.J. Blakemore. Interactions between Carnosine and Zinc and Copper: Implications for Neuromodulation and Neuroprotection. Biochemistry Moscow. Vol. 65 (7) 2000, 949-960.
Wang AM, Ma C, Xie ZH, Shen F. Use of carnosine as a natural anti-senescence drug for human beings. Biochemistry (Mosc) 2000 Jul;65(7):869-71.
Witschi A, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. (1992)
Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem. (2003)
Bates C.J, Manssor M.A, Gregory J, Pentieva K, Prentice A. Correlates of plasma homocysteine, cysteine and cysteinyl-glycine in respondents in the British National Diet and Nutrition Survey of Young People Aged 4–18 years, and a com-parison with the Survey of People Aged 65 Years and Over. Br. J. Nutr. 2002;87:71–79. 10.1079/BJN2001479
Wefers H, Sies H; Sies (1988). "The protection of ascorbate and glutathione against microsomal lipid peroxidation is dependent on Vitamin E". European Journal of Biochemistry 174 (2): 353–357. doi:10.1111/j.1432-1033.1988.tb14105.x. PMID 3383850.
Traber MG, Atkinson J; Atkinson (2007). "Vitamin E, Antioxidant and Nothing More". Free radical biology & medicine 43 (1): 4–15. doi:10.1016/j.freeradbiomed.2007.03.024. PMC 2040110. PMID 17561088.
Sharoni, Y; Linnewiel-Hermoni, K; Zango, G; Khanin, M; Salman, H; Veprik, A; Danilenko, M; Levy, J (2012). "The role of lycopene and its derivatives in the regulation of transcription systems: Implications for cancer prevention". American Journal of Clinical Nutrition 96 (5): 1173S–8S. doi:10.3945/ajcn.112.034645. PMID
Qualified Health Claims: Letter Regarding Tomatoes and Prostate Cancer (Lycopene Health Claim Coalition) (Docket No. 2004Q-0201)". US Food and Drug Administration. 8 November 2005.
Kamiloglu, S.; Demirci, M.; Selen, S.; Toydemir, G.; Boyacioglu, D.; Capanoglu, E. (2014). "Home processing of tomatoes (Solanum lycopersicum): Effects onin vitrobioaccessibility of total lycopene, phenolics, flavonoids, and antioxidant capacity". Journal of the Science of Food and Agriculture 94 (11): 2225–33. doi:10.1002/jsfa.6546. PMID 24375495.
Johnson EJ, Hammond BR, Yeum KJ, et al. (June 2000). "Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density". Am. J. Clin. Nutr. 71 (6): 1555–62. PMID 10837298.
Landrum, J., et al. Serum and macular pigment response to 2.4 mg dosage of lutein. in ARVO. 2000.
Berendschot TT, Goldbohm RA, Klöpping WA, van de Kraats J, van Norel J, van Norren D (October 2000). "Influence of lutein supplementation on macular pigment, assessed with two objective techniques". Invest. Ophthalmol. Vis. Sci. 41 (11): 3322–6. PMID 11006220.
Aleman TS, Duncan JL, Bieber ML, et al. (July 2001). "Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome". Invest. Ophthalmol. Vis. Sci. 42 (8): 1873–81. PMID 11431456.
Duncan JL, Aleman TS, Gardner LM, et al. (March 2002). "Macular pigment and lutein supplementation in choroideremia". Exp. Eye Res. 74 (3): 371–81. doi:10.1006/exer.2001.1126. PMID 12014918.
Johnson EJ, Neuringer M, Russell RM, Schalch W, Snodderly DM (February 2005). "Nutritional manipulation of primate retinas, III: Effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys". Invest. Ophthalmol. Vis. Sci. 46 (2): 692–702. doi:10.1167/iovs.02-1192. PMID 15671301.
Richer S, Stiles W, Statkute L, et al. (April 2004). "Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial)". Optometry 75 (4): 216–30. doi:10.1016/s1529-1839(04)70049-4. PMID 15117055.
Age-Related Eye Disease Study Research Group (October 2001). "A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8". Arch. Ophthalmol. 119 (10): 1417–36. doi:10.1001/archopht.119.10.1417. PMC 1462955. PMID 11594942.
SanGiovanni JP, Chew EY, Clemons TE, et al. (September 2007). "The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22". Arch. Ophthalmol. 125 (9): 1225–32. doi:10.1001/archopht.125.9.1225. PMID 17846363.
"Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and serum in the Carotenoids in the Age-Related Eye Disease Study, an Ancillary Study of the Women's Health Initiative."
"Dietary supplementation: effects on visual performance and occurrence of AMD and cataracts.". Current medical research and opinion 26 (8): 2011–23. doi:10.1185/03007995.2010.494549. PMID 20590393.
Stringham, James M.; et al. (January–February 2010). "The Influence of Dietary Lutein and Zeaxanthin on Visual Performance". Journal of Food Science 75 (1): R24–R29. doi:10.1111/j.1750-3841.2009.01447.x. PMID 20492192. Retrieved January 15, 2013.
Nature is our science.
Vegetable and bioidentical
The efficiency of all Natural Energy products is to be found in the way in which the active ingredients are adapted to be absorbed by the body as efficiently as possible.
Read more >>
Quality is essential to launch a safe and good product on the market. A good product contains active ingredients in a forms available to the human body so that these ingredients show positive health effects when used correctly.
Read more >>
In our laboratories these ingredients are optimized in innovative ways in order to obtain supplements that are distinguished by their exceptional efficiency and maximum safety.
Read more >>